Company intelligence / Profile preview

CardiaCare

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Completed first-in-human study in 2022 with 10 patients showing strong safety profile, significant acute reduction in premature atrial complexes (PACs), and long-term decrease in AF recurrence. Successfully completed RCT pilot feasibility trial. Currently preparing to launch pivotal studies by end of 2025.

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital therapeuticNeuromodulation therapy
Industry: Digital Health Medical Devices

Partnerships

Dr. Reddy's Laboratories

Beyond the preview

Go deeper on CardiaCare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardiaCare.

Explore the full profile